Compensation between Vav-1 and Vav-2 in B cell development and antigen receptor signaling
10.1038/88756
Crossref journal-article
Springer Science and Business Media LLC
Nature Immunology (297)
Bibliography

Tedford, K., Nitschke, L., Girkontaite, I., Charlesworth, A., Chan, G., Sakk, V., Barbacid, M., & Fischer, K.-D. (2001). Compensation between Vav-1 and Vav-2 in B cell development and antigen receptor signaling. Nature Immunology, 2(6), 548–555.

Authors 8
  1. Kerry Tedford (first)
  2. Lars Nitschke (additional)
  3. Irute Girkontaite (additional)
  4. Amanda Charlesworth (additional)
  5. Gordon Chan (additional)
  6. Vadim Sakk (additional)
  7. Mariano Barbacid (additional)
  8. Klaus-Dieter Fischer (additional)
References 57 Referenced 142
  1. Benschop, R. J. & Cambier, J. C. B cell development: signal transduction by antigen receptors and their surrogates. Curr. Opin. Immunol. 11, 143–151 (1999). (10.1016/S0952-7915(99)80025-9) / Curr. Opin. Immunol. by RJ Benschop (1999)
  2. Pillai, S. The chosen few? Positive selection and the generation of naive B lymphocytes. Immunity 10, 493–502 (1999). (10.1016/S1074-7613(00)80049-7) / Immunity by S Pillai (1999)
  3. Carsetti, R., Kohler, G. & Lamers, M. C. Transitional B cells are the target of negative selection in the B cell compartment. J. Exp. Med. 181, 2129–2140 (1995). (10.1084/jem.181.6.2129) / J. Exp. Med. by R Carsetti (1995)
  4. Melamed, D., Benschop, R. J., Cambier, J. C. & Nemazee, D. Developmental regulation of B lymphocyte immune tolerance comparmentalizes clonal selection from receptor selection. Cell 92, 173–182 (1998). (10.1016/S0092-8674(00)80912-5) / Cell by D Melamed (1998)
  5. Kurosaki, T. Functional dissection of BCR signaling pathways. Curr. Opin. Immunol. 12, 276–281 (2000). (10.1016/S0952-7915(00)00087-X) / Curr. Opin. Immunol. by T Kurosaki (2000)
  6. Kerner, J. D. et al. Impaired expansion of mouse B cell progenitors lacking Btk. Immunity 3, 301–312 (1995). (10.1016/1074-7613(95)90115-9) / Immunity by JD Kerner (1995)
  7. Khan, W. N. et al. Defective B cell development and function in Btk-deficient mice. Immunity 3, 283–299 (1995). (10.1016/1074-7613(95)90114-0) / Immunity by WN Khan (1995)
  8. Fruman, D. A. et al. Impaired B cell development and proliferation in absence of phosphoinositide 3-kinase p85α. Science 283, 393–397 (1999). (10.1126/science.283.5400.393) / Science by DA Fruman (1999)
  9. Suzuki, H. et al. Xid-like immunodeficiency in mice with disruption of the p85α subunit of phosphoinositide 3-kinase. Science 283, 390–392 (1999). (10.1126/science.283.5400.390) / Science by H Suzuki (1999)
  10. Jumaa, H. et al. Abnormal development and function of B lymphocytes in mice deficient for the signaling adaptor protein SLP-65. Immunity 11, 547–554 (1999). (10.1016/S1074-7613(00)80130-2) / Immunity by H Jumaa (1999)
  11. Pappu, R. et al. Requirement for B cell linker protein (BLNK) in B cell development. Science 286, 1949–1954 (1999). (10.1126/science.286.5446.1949) / Science by R Pappu (1999)
  12. Hayashi, K. et al. The B cell-restricted adaptor BASH is required for normal development and antigen receptor-mediated activation of B cells. Proc. Natl Acad. Sci. USA 97, 2755–2760 (2000). (10.1073/pnas.040575697) / Proc. Natl Acad. Sci. USA by K Hayashi (2000)
  13. Xu, S. et al. B cell development and activation defects resulting in xid-like immunodeficiency in BLNK/SLP-65-deficient mice. Int. Immunol. 12, 397–404 (2000). (10.1093/intimm/12.3.397) / Int. Immunol. by S Xu (2000)
  14. Wang, D. et al. Phospholipase Cγ2 is essential in the functions of B cell and several Fc receptors. Immunity 13, 25–35 (2000). (10.1016/S1074-7613(00)00005-4) / Immunity by D Wang (2000)
  15. Fruman, D. A., Satterthwaite, A. B. & Witte, O. N. Xid-like phenotypes: a B cell signalosome takes shape. Immunity 13, 1–3 (2000). (10.1016/S1074-7613(00)00002-9) / Immunity by DA Fruman (2000)
  16. Bishop, A. L. & Hall, A. Rho GTPases and their effector proteins. Biochem. J. 348, 241–255 (2000). (10.1042/bj3480241) / Biochem. J. by AL Bishop (2000)
  17. Bustelo, X. R. Regulatory and signaling properties of the Vav family. Mol. Cell Biol. 20, 1461–1477 (2000). (10.1128/MCB.20.5.1461-1477.2000) / Mol. Cell Biol. by XR Bustelo (2000)
  18. Bustelo, X. R., Rubin, S. D., Suen, K. L., Carrasco, D. & Barbacid, M. Developmental expression of the vav protooncogene. Cell. Growth Differ. 4, 297–308 (1993). / Cell. Growth Differ. by XR Bustelo (1993)
  19. Schuebel, K. E. et al. Isolation and characterization of murine vav-2, a member of the vav family of proto-oncogenes. Oncogene 13, 363–371 (1996). / Oncogene by KE Schuebel (1996)
  20. Movilla, N. & Bustelo, X. R. Biological and regulatory properties of Vav-3, a new member of the Vav family of oncoproteins. Mol. Cell Biol. 19, 7870–7885 (1999). (10.1128/MCB.19.11.7870) / Mol. Cell Biol. by N Movilla (1999)
  21. Fischer, K. D., Tedford, K. & Penninger, J. M. Vav links antigen-receptor signaling to the actin cytoskeleton. Semin. Immunol. 10, 317–327 (1998). (10.1006/smim.1998.0124) / Semin. Immunol. by KD Fischer (1998)
  22. Fischer, K. D. et al. Defective T-cell receptor signalling and positive selection of Vav- deficient CD4+ CD8+ thymocytes. Nature 374, 474–7 (1995). (10.1038/374474a0) / Nature by KD Fischer (1995)
  23. Turner, M. et al. A requirement for the Rho-family GTP exchange factor Vav in positive and negative selection of thymocytes. Immunity 7, 451–460 (1997). (10.1016/S1074-7613(00)80367-2) / Immunity by M Turner (1997)
  24. Kong, Y. Y. et al. Vav regulates peptide-specific apoptosis in thymocytes. J. Exp. Med. 188, 2099–2111 (1998). (10.1084/jem.188.11.2099) / J. Exp. Med. by YY Kong (1998)
  25. Krawczyk, C. et al. Cbl-b is a negative regulator of receptor clustering and raft aggregation in T cells. Immunity 13, 463–473 (2000). (10.1016/S1074-7613(00)00046-7) / Immunity by C Krawczyk (2000)
  26. Zhang, R., Alt, F. W., Davidson, L., Orkin, S. H. & Swat, W. Defective signalling through the T- and B-cell antigen receptors in lymphoid cells lacking the vav proto-oncogene. Nature 374, 470–473 (1995). (10.1038/374470a0) / Nature by R Zhang (1995)
  27. Fischer, K. D. et al. Vav is a regulator of cytoskeletal reorganization mediated by the T- cell receptor. Curr. Biol. 8, 554–562 (1998). (10.1016/S0960-9822(98)70224-6) / Curr. Biol. by KD Fischer (1998)
  28. Tarakhovsky, A. et al. Defective antigen receptor-mediated proliferation of B and T cells in the absence of Vav. Nature 374, 467–470 (1995). (10.1038/374467a0) / Nature by A Tarakhovsky (1995)
  29. Holsinger, L. J. et al. Defects in actin-cap formation in Vav-deficient mice implicate an actin requirement for lymphocyte signal transduction. Curr. Biol. 8, 563–572 (1998). (10.1016/S0960-9822(98)70225-8) / Curr. Biol. by LJ Holsinger (1998)
  30. O'Rourke, L. M. et al. CD19 as a membrane-anchored adaptor protein of B lymphocytes: costimulation of lipid and protein kinases by recruitment of Vav. Immunity 8, 635–645 (1998). (10.1016/S1074-7613(00)80568-3) / Immunity by LM O'Rourke (1998)
  31. Bachmann, M. F. et al. The guanine-nucleotide exchange factor Vav is a crucial regulator of B cell receptor activation and B cell responses to nonrepetitive antigens. J. Immunol. 163, 137–142 (1999). (10.4049/jimmunol.163.1.137) / J. Immunol. by MF Bachmann (1999)
  32. Gulbranson-Judge, A. et al. Defective immunoglobulin class switching in Vav–deficient mice is attributable to compromised T cell help. Eur. J. Immunol. 29, 477–487 (1999). (10.1002/(SICI)1521-4141(199902)29:02<477::AID-IMMU477>3.0.CO;2-V) / Eur. J. Immunol. by A Gulbranson-Judge (1999)
  33. Loder, F. et al. B cell development in the spleen takes place in discrete steps and is determined by the quality of the B cell receptor-derived signals. J. Exp. Med. 190, 75–89 (1999). (10.1084/jem.190.1.75) / J. Exp. Med. by F Loder (1999)
  34. Klaus, G. G., Holman, M., Johnson-Leger, C., Elgueta-Karstegl, C. & Atkins, C. A re-evaluation of the effects of X-linked immunodeficiency (xid) mutation on B cell differentiation and function in the mouse. Eur. J. Immunol. 27, 2749–2756 (1997). (10.1002/eji.1830271102) / Eur. J. Immunol. by GG Klaus (1997)
  35. Doody, G. M. et al. Vav-2 controls NFAT-dependent transcription in B- but not T-lymphocytes. EMBO J. 19, 6173–6184 (2000). (10.1093/emboj/19.22.6173) / EMBO J. by GM Doody (2000)
  36. Moores, S. L. et al. Vav family proteins couple to diverse cell surface receptors. Mol. Cell Biol. 20, 6364–7633 (2000). (10.1128/MCB.20.17.6364-6373.2000) / Mol. Cell Biol. by SL Moores (2000)
  37. Deckert, M., Tartare-Deckert, S., Couture, C., Mustelin, T. & Altman, A. Functional and physical interactions of Syk family kinases with the Vav proto-oncogene product. Immunity 5, 591–604 (1996). (10.1016/S1074-7613(00)80273-3) / Immunity by M Deckert (1996)
  38. Wu, J., Zhao, Q., Kurosaki, T. & Weiss, A. The Vav binding site (Y315) in ZAP-70 is critical for antigen receptor- mediated signal transduction. J. Exp. Med. 185, 1877–1882 (1997). (10.1084/jem.185.10.1877) / J. Exp. Med. by J Wu (1997)
  39. Fu, C., Turck, C. W., Kurosaki, T. & Chan, A. C. BLNK: a central linker protein in B cell activation. Immunity 9, 93–103 (1998). (10.1016/S1074-7613(00)80591-9) / Immunity by C Fu (1998)
  40. Wienands, J. et al. SLP-65: a new signaling component in B lymphocytes which requires expression of the antigen receptor for phosphorylation. J. Exp. Med. 188, 791–795 (1998). (10.1084/jem.188.4.791) / J. Exp. Med. by J Wienands (1998)
  41. Kelly, M. E. & Chan, A. C. Regulation of B cell function by linker proteins. Curr. Opin. Immunol. 12, 267–275 (2000). (10.1016/S0952-7915(00)00086-8) / Curr. Opin. Immunol. by ME Kelly (2000)
  42. Han, J. et al. Role of substrates and products of PI 3-kinase in regulating activation of Rac-related guanosine triphosphatases by Vav. Science 279, 558–560 (1998). (10.1126/science.279.5350.558) / Science by J Han (1998)
  43. Fu, C. & Chan, A. C. Identification of two tyrosine phosphoproteins, pp70 and pp68, which interact with phospholipase Cγ, Grb2, and Vav after B cell antigen receptor activation. J. Biol. Chem. 272, 27362–27368 (1997). (10.1074/jbc.272.43.27362) / J. Biol. Chem. by C Fu (1997)
  44. Hashimoto, S. et al. Identification of the SH2 domain binding protein of Bruton's tyrosine kinase as BLNK—functional significance of Btk-SH2 domain in B-cell antigen receptor-coupled calcium signaling. Blood 94, 2357–2364 (1999). (10.1182/blood.V94.7.2357.419k40_2357_2364) / Blood by S Hashimoto (1999)
  45. Su, Y. W. et al. Interaction of SLP adaptors with the SH2 domain of Tec family kinases. Eur J. Immunol. 29, 3702–3711 (1999). (10.1002/(SICI)1521-4141(199911)29:11<3702::AID-IMMU3702>3.0.CO;2-R) / Eur J. Immunol. by YW Su (1999)
  46. Aman, M. J. & Ravichandran, K. S. A requirement for lipid rafts in B cell receptor induced Ca(2+) flux. Curr. Biol. 10, 393–396 (2000). (10.1016/S0960-9822(00)00415-2) / Curr. Biol. by MJ Aman (2000)
  47. Guo, B., Kato, R. M., Garcia-Lloret, M., Wahl, M. I. & Rawlings, D. J. Engagement of the human pre-B cell receptor generates a lipid raft-dependent calcium signaling complex. Immunity 13, 243–253 (2000). (10.1016/S1074-7613(00)00024-8) / Immunity by B Guo (2000)
  48. Weng, W. K., Jarvis, L. & LeBien, T. W. Signaling through CD19 activates Vav/mitogen-activated protein kinase pathway and induces formation of a CD19/Vav/phosphatidylinositol 3-kinase complex in human B cell precursors. J. Biol. Chem. 269, 32514–32521 (1994). (10.1016/S0021-9258(18)31664-8) / J. Biol. Chem. by WK Weng (1994)
  49. Tedder, T. F., Inaoki, M. & Sato, S. The CD19-CD21 complex regulates signal transduction thresholds governing humoral immunity and autoimmunity. Immunity 6, 107–118 (1997). (10.1016/S1074-7613(00)80418-5) / Immunity by TF Tedder (1997)
  50. Crespo, P., Schuebel, K. E., Ostrom, A. A., Gutkind, J. S. & Bustelo, X. R. Phosphotyrosine-dependent activation of Rac-1 GDP/GTP exchange by the vav proto-oncogene product. Nature 385, 169–172 (1997). (10.1038/385169a0) / Nature by P Crespo (1997)
  51. Schuebel, K. E., Movilla, N., Rosa, J. L. & Bustelo, X. R. Phosphorylation-dependent and constitutive activation of Rho proteins by wild-type and oncogenic Vav-2. EMBO J. 17, 6608–6621 (1998). (10.1093/emboj/17.22.6608) / EMBO J. by KE Schuebel (1998)
  52. Tybulewicz, V. L., Crawford, C. E., Jackson, P. K., Bronson, R. T. & Mulligan, R. C. Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene. Cell 65, 1153–1163 (1991). (10.1016/0092-8674(91)90011-M) / Cell by VL Tybulewicz (1991)
  53. Ogilvy, S. et al. Transcriptional regulation of Vav, a gene expressed throughout the hematopoietic compartment. Blood 91, 419–430 (1998). (10.1182/blood.V91.2.419) / Blood by S Ogilvy (1998)
  54. Zmuidzinas, A. et al. The Vav proto-oncogene is required early in embryogenesis but not for hematopoietic development in vitro. EMBO J. 14, 1–11 (1995). (10.1002/j.1460-2075.1995.tb06969.x) / EMBO J. by A Zmuidzinas (1995)
  55. Rolink, A., Kudo, A., Karasuyama, H., Kikuchi, Y. & Melchers, F. Long-term proliferating early pre B cell lines and clones with the potential to develop to surface Ig-positive, mitogen reactive B cells in vitro and in vivo. EMBO J. 10, 327–336 (1991). (10.1002/j.1460-2075.1991.tb07953.x) / EMBO J. by A Rolink (1991)
  56. Fong, G. H., Rossant, J., Gertsenstein, M. & Breitman, M. L. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376, 66–70 (1995). (10.1038/376066a0) / Nature by GH Fong (1995)
  57. Rolink, A., Melchers, F. & Andersson, J. The SCID but not the RAG-2 gene product is required for S mu-S epsilon heavy chain class switching. Immunity 5, 319–330 (1996). (10.1016/S1074-7613(00)80258-7) / Immunity by A Rolink (1996)
Dates
Type When
Created 23 years, 1 month ago (July 26, 2002, 4:43 a.m.)
Deposited 2 years, 3 months ago (May 18, 2023, 6:23 p.m.)
Indexed 5 months ago (March 30, 2025, 10:28 a.m.)
Issued 24 years, 3 months ago (June 1, 2001)
Published 24 years, 3 months ago (June 1, 2001)
Published Print 24 years, 3 months ago (June 1, 2001)
Funders 0

None

@article{Tedford_2001, title={Compensation between Vav-1 and Vav-2 in B cell development and antigen receptor signaling}, volume={2}, ISSN={1529-2916}, url={http://dx.doi.org/10.1038/88756}, DOI={10.1038/88756}, number={6}, journal={Nature Immunology}, publisher={Springer Science and Business Media LLC}, author={Tedford, Kerry and Nitschke, Lars and Girkontaite, Irute and Charlesworth, Amanda and Chan, Gordon and Sakk, Vadim and Barbacid, Mariano and Fischer, Klaus-Dieter}, year={2001}, month=jun, pages={548–555} }